Log In
Print this Print this

actoxumab/bezlotoxumab (MDX-066/MDX-1388) (MK-3415A)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionCombination of bezlotoxumab, a human mAb targeting Clostridium difficile toxin B (TcdB), and actoxumab, a human mAb targeting TcdA
Molecular Target Clostridium difficile toxin B (TcdB) ; Clostridium difficile toxin A (TcdA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation
Partner Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today